/
NSPR
$0.68-$0.04 (-5.60%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$33.7M
47M shares
52-week range
$0.63 – $2.93
2% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.96%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-4.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M | $3.7M | $2.5M | $4.5M | $5.2M | $6.2M | $7.0M | $9.0M |
| Cost of revenue | $2.6M | $3.0M | $2.4M | $3.7M | $4.1M | $4.4M | $5.5M | $6.3M |
| Gross profit | $995.0K | $756.0K | $83.0K | $754.0K | $1.1M | $1.8M | $1.5M | $2.6M |
| Gross margin | 27.6% | 20.3% | 3.3% | 16.8% | 21.6% | 29.1% | 21.5% | 29.5% |
| R&D | $1.5M | $3.0M | $2.2M | $5.2M | $7.8M | $8.0M | $13.6M | $15.0M |
| Operating income | −$7.6M | −$9.8M | −$10.4M | −$14.7M | −$18.7M | −$21.1M | −$33.5M | −$49.1M |
| EBITDA | −$7.5M | −$9.7M | −$10.2M | −$14.6M | −$18.3M | −$19.6M | −$31.7M | −$48.2M |
| Net income | −$7.2M | −$10.0M | −$10.5M | −$14.9M | −$18.5M | −$19.9M | −$32.0M | −$48.8M |
| Net margin | -201.1% | -269.8% | -424.3% | -331.9% | -357.6% | -321.0% | -456.6% | -543.3% |
| EPS (diluted) | -247.50 | -72.00 | -6.90 | -2.03 | -2.35 | -0.82 | -0.76 | -0.76 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-0.74 | $-0.87–$-0.66 | 1 |
| 2027 | $22M | $-0.61 | $-0.71–$-0.54 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
InspireMD, Inc.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
www.inspiremd.com- Employees
- 127
- IPO / List date
- Aug 22, 1997
- HQ
- MIAMI, FL
Held by traders on TradeandTell
No one on the platform currently holds NSPR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 17,609 | $28.7K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2021-04-27 | 1-for-15reverse |
| 2019-04-01 | 1-for-50reverse |
| 2018-02-08 | 1-for-35reverse |
| 2016-10-11 | 1-for-25reverse |
| 2015-10-01 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded NSPR yet.
